Repligen | RGEN - Equity Capital And Reserves


Repligen reported $2.11B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Agilent USD 7.12B 214M Mar/2026
Align Technology USD 4.15B 100.27M Mar/2026
Bio Techne USD 2.09B 74.32M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Bruker USD 2.46B 35.9M Dec/2025
Charles River Laboratories USD 2.9B 265.94M Mar/2026
Danaher USD 52.95B 415M Mar/2026
Dentsply International USD 1.32B 21M Mar/2026
General Electric Aerospace USD 18.06B 841M Mar/2026
Henry Schein USD 3.27B 21M Mar/2026
Illumina USD 2.68B 47M Mar/2026
IQVIA Holdings USD 6.22B 282M Mar/2026
Mettler Toledo International USD -41.88M 18.25M Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
OraSure Technologies USD 313.32M 27.5M Mar/2026
Pacific Biosciences Of California USD 2.37M 2.98M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Repligen USD 2.11B 666K Mar/2026
Revvity USD 7.25B 125.54M Dec/2025
Standard Biotools USD 561.12M 136.83M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Waters USD 2.56B 230.55M Dec/2025
West Pharmaceutical Services USD 2.99B 185.6M Mar/2026